Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenx to Participate at Upcoming Investor Conferences
01:00am, Tuesday, 05'th Nov 2024
November 5, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda
Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat
01:29pm, Thursday, 31'st Oct 2024
argenx reported strong Q3 results with the sales outperformance being primarily driven by the gMG uptake of Vyvgart. Initial contribution from the CIDP launch also exceeded expectations. The growth ou
argenx SE (ARGX) Q3 2024 Earnings Call Transcript
01:08pm, Thursday, 31'st Oct 2024
argenx SE (NASDAQ:ARGX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Beth DelGiacco – Vice President, Corporate Communications and Investor Relations Tim Van Ha
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
02:00am, Thursday, 31'st Oct 2024
$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference call to
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
01:00am, Thursday, 24'th Oct 2024
October 24, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda
Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of re
3 Best Earnings Acceleration Stocks to Buy in a Strong Q4
04:06pm, Friday, 04'th Oct 2024
With the advent of a strong fourth quarter, it's prudent to invest in stocks exhibiting solid earnings acceleration such as Argenx, Alphatec Holdings and Olin Corporation.
Are Medical Stocks Lagging Argenx (ARGX) This Year?
10:41am, Friday, 04'th Oct 2024
Here is how argenex SE (ARGX) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year.
argenx: Myositis Data Could Add Billions In Value
09:06pm, Tuesday, 24'th Sep 2024
argenx remains a dominant player in the anti-FcRn market, with Vyvgart approved for gMG, CIDP, and ITP in Japan. The ALKIVIA trial aims to expand Vyvgart's use in myositis, a rare autoimmune disease a
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
01:00am, Thursday, 19'th Sep 2024
ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk
Four Biotech Stocks Rally Toward Buy Points As Funds Load Up
01:31pm, Friday, 06'th Sep 2024
Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.
Argenx (ARGX) Moves 4.0% Higher: Will This Strength Last?
09:41am, Friday, 06'th Sep 2024
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
argenx to Present at Upcoming Investor Conferences
01:00am, Wednesday, 28'th Aug 2024
August 28, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today
Are Medical Stocks Lagging Argenx (ARGX) This Year?
10:46am, Friday, 16'th Aug 2024
Here is how argenex SE (ARGX) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Biotech stocks: Which drugmakers are worth a buy?
05:13pm, Monday, 12'th Aug 2024
While the pharma space has seen growing excitement over weight-loss drugs from Eli Lilly (LLY) and Novo Nordisk's (NVO) latest earnings, investors are increasingly curious over the types of innovation
